Sionna Therapeutics (NASDAQ:SION) Shares Down 7.7% – Here’s What Happened

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) traded down 7.7% during mid-day trading on Monday . The stock traded as low as $39.75 and last traded at $39.5030. 75,045 shares were traded during trading, a decline of 78% from the average session volume of 342,475 shares. The stock had previously closed at $42.82.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen downgraded Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. JonesTrading increased their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Wedbush initiated coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target for the company. Finally, Stifel Nicolaus increased their price target on Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Trading Down 4.3%

The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -21.25 and a beta of 1.30. The stock has a fifty day simple moving average of $40.33 and a 200-day simple moving average of $39.88.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Sell-side analysts forecast that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Peter A. Thompson sold 184,639 shares of Sionna Therapeutics stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This trade represents a 6.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,717,962 shares of company stock valued at $77,571,889 over the last three months. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SION. Goldman Sachs Group Inc. acquired a new stake in shares of Sionna Therapeutics during the first quarter worth $667,000. Woodline Partners LP acquired a new stake in shares of Sionna Therapeutics during the first quarter worth $837,000. Geode Capital Management LLC grew its stake in Sionna Therapeutics by 113.4% in the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after acquiring an additional 153,712 shares during the period. Rhumbline Advisers acquired a new position in Sionna Therapeutics in the second quarter valued at about $307,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Sionna Therapeutics in the second quarter valued at about $118,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.